U.S. Markets open in 2 hrs 33 mins

Precipio, Inc. (PRPO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8651+0.0235 (+2.79%)
At close: 04:00PM EDT
0.8722 +0.01 (+0.82%)
After hours: 04:15PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8416
Bid0.0000 x 2200
Ask0.8700 x 1000
Day's Range0.8200 - 0.8726
52 Week Range0.7720 - 2.7400
Avg. Volume214,151
Market Cap19.645M
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.8480
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • GlobeNewswire

    Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™

    Adding customer segment exceeding $100M in market potentialNEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy). Following an upcoming training program and onboarding of their national coverage, this distribution channel partner’s sales team will begin promoting and driving sales of the HemeScreen platform

  • GlobeNewswire

    Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales

    Precipio continues to build strong team in anticipation of substantial growth in the next 12 monthsNEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Sharon Robins as the Company’s Senior Director of Laboratory & Hospital Sales for the Product’s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (a

  • GlobeNewswire

    Precipio Launches New 1-Step Technology for all HemeScreen Assays

    New technology enables same day test results by eliminating extra confirmation stepNEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s customers using HemeScreen in their laboratory will have the option of upgrading to the 1-step assay, or remaining with the current assay. While the first generation of panels required a 2-step process that included a